To access the full text documents, please follow this link: http://hdl.handle.net/2445/127545

Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations
Graus Ribas, Francesc; Saiz Hinajeros, Albert; Lai, Marina; Bruna, Jordi; López, Francisca; Sabater, Lidia; Blanco, Yolanda; Rey, María Jesús; Ribalta Farrés, Teresa María; Dalmau Obrador, Josep
Objective: To report the frequency and type of antibodies against neuronal surface antigens (NSA-ab) in limbic encephalitis (LE). Methods: Analysis of clinical features, neuropathologic findings, and detection of NSA-ab using immunochemistry on rat tissue and neuronal cultures in a series of 45 patients with paraneoplastic (23) or idiopathic (22) LE. Results: NSA-ab were identified in 29 patients (64%; 12 paraneoplastic, 17 idiopathic). Thirteen patients had voltage-gated potassium channels (VGKC)-ab, 11 novel NSA (nNSA)-ab, and 5 NMDA receptor (NMDAR)-ab. nNSA-ab did not identify a common antigen and were more frequent in paraneoplastic than idiopathic LE (39% vs 9%; p = 0.03). When compared with VGKC-ab or NMDAR-ab, the nNSA associated more frequently with intraneuronal antibodies (11% vs 73%; p = 0.001). Of 12 patients (9 nNSA-ab, 2 VGKC-ab, 1 NMDAR-ab) with paraneoplastic LE and NSA-ab, concomitant intraneuronal antibodies occurred in 9 (75%). None of these 12 patients improved with immunotherapy. The autopsy of three of them showed neuronal loss, microgliosis, and cytotoxic T cell infiltrates in the hippocampus and amygdala. These findings were compatible with a T-cell mediated neuronal damage. In contrast, 13 of 17 (76%) patients with idiopathic LE and NSA-ab (8 VGKC-ab, 4 NMDAR-ab, 1 nNSA-ab) and 1 of 5 (20%) without antibodies had clinical improvement (p = 0.04). Conclusions: In paraneoplastic limbic encephalitis (LE), novel antibodies against neuronal surface antigens (nNSA-ab) occur frequently, coexist with antibodies against intracellular antigens, and these cases are refractory to immunotherapy. In idiopathic LE, the likelihood of improvement is significantly higher in patients with NSA-ab than in those without antibodies.
-Encefalitis
-Immunoglobulines
-Immunoteràpia
-Encephalitis
-Immunoglobulins
-Immunotheraphy
(c) American Academy of Neurology, 2008
Article
Article - Published version
Lippincott, Williams & Wilkins. Wolters Kluwer Health
         

Show full item record

Related documents

Other documents of the same author

Graus Ribas, Francesc; Saiz Hinajeros, Albert; Lai, Marina; Bruna, Jordi; López, Francisca; Sabater, Lidia; Blanco, Yolanda; Rey, Maria Jesús; Ribalta, Teresa; Dalmau Obrador, Josep
Graus Ribas, Francesc; Saiz Hinajeros, Albert; Lai, Marina; Bruna, Jordi; López, Francisca; Sabater, Lidia; Blanco, Yolanda; Rey, Maria Jesús; Ribalta, Teresa; Dalmau Obrador, Josep
Höftberger, Romana; Sepulveda, María; Armangué, Thaís; Blanco, Yolanda; Rostásy, Kevin; Cobo Calvo, Álvaro; Olascoaga, Javier; Ramió Torrentà, Lluís; Reindl, Markus; Benito León, Julián; Casanova, Bonaventura; Arrambide, Georgina; Sabater, Lidia; Graus Ribas, Francesc; Dalmau Obrador, Josep; Saiz Hinajeros, Albert
Höftberger, Romana; Sepúlveda, María; Armangué, Thaís; Blanco, Yolanda; Rostásy, Kevin; Cobo Calvo, Álvaro; Olascoaga, Javier; Ramió Torrentà, Lluís; Reindl, Markus; Benito León, Julián; Casanova, Bonaventura; Arrambide, Georgina; Sabater, Lidia; Graus Ribas, Francesc; Dalmau Obrador, Josep; Saiz Hinajeros, Albert
Sabater, Lidia; Höftberger, Romana; Boronat, Anna; Saiz Hinajeros, Albert; Dalmau Obrador, Josep; Graus Ribas, Francesc
 

Coordination

 

Supporters